comparemela.com
Home
Live Updates
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials : comparemela.com
TILT Biotherapeutics Announces Final Close of €22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials
TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows
Related Keywords
China ,
Boston ,
Massachusetts ,
United States ,
Helsinki ,
Eteläuomen Läi ,
Finland ,
Guangdong ,
Jilin ,
Finnish ,
Chinese ,
Akseli Hemminki ,
Hermann Hauser ,
Timo Ahopelto ,
Daniel Gooch ,
Aino Kalervo ,
Schwierige Zeiten ,
European Innovation Council Fund ,
University Of Helsinki ,
European Innovation Council ,
Pfizer Alliance ,
European Commission ,
Scius Communications ,
Merck Co Inc ,
Merck Kga ,
Fund Board ,
Merck Kgaa ,
Stephen Industries Inc Oy ,
Fund As Investment Advisor ,
European Investment Bank ,
Lifeline Ventures ,
Founding Partner ,
European Innovation ,
Finnish Industry Investment ,
Business Finland ,
Tilt ,
Iotherapeutics ,
Nnounces ,
Final ,
Close ,
Billion ,
Financing ,
Hound ,
Advance ,
Hase ,
Ncology ,
Immunotherapy ,
Trials ,
comparemela.com © 2020. All Rights Reserved.